- Home
- CASI vs BNR Comparison
CASI vs BNR Comparison
Compare CASI & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- BNR
- Stock Information
- Founded
- CASI 1991
- BNR 2014
- Country
- CASI China
- BNR China
- Employees
- CASI N/A
- BNR N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- BNR Medical Specialities
- Sector
- CASI Health Care
- BNR Health Care
- Exchange
- CASI Nasdaq
- BNR Nasdaq
- Market Cap
- CASI 35.8M
- BNR 38.3M
- IPO Year
- CASI 1996
- BNR 2020
- Fundamental
- Price
- CASI $1.84
- BNR $9.02
- Analyst Decision
- CASI Strong Buy
- BNR
- Analyst Count
- CASI 1
- BNR 0
- Target Price
- CASI $4.00
- BNR N/A
- AVG Volume (30 Days)
- CASI 305.0K
- BNR 24.9K
- Earning Date
- CASI 11-13-2025
- BNR 09-08-2025
- Dividend Yield
- CASI N/A
- BNR N/A
- EPS Growth
- CASI N/A
- BNR N/A
- EPS
- CASI N/A
- BNR N/A
- Revenue
- CASI $31,564,000.00
- BNR $74,862,782.00
- Revenue This Year
- CASI N/A
- BNR $136.32
- Revenue Next Year
- CASI N/A
- BNR N/A
- P/E Ratio
- CASI N/A
- BNR N/A
- Revenue Growth
- CASI 36.64
- BNR 5.20
- 52 Week Low
- CASI $1.09
- BNR $2.18
- 52 Week High
- CASI $7.50
- BNR $11.12
- Technical
- Relative Strength Index (RSI)
- CASI 51.04
- BNR 55.51
- Support Level
- CASI $1.77
- BNR $8.91
- Resistance Level
- CASI $2.08
- BNR $9.77
- Average True Range (ATR)
- CASI 0.20
- BNR 0.54
- MACD
- CASI 0.02
- BNR -0.04
- Stochastic Oscillator
- CASI 71.84
- BNR 62.13
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.